NotizieBenzingaAmgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Benzinga 2026.10.20 13:06 (GMT+0) Apri Benzinga Altre notizie Rosenblatt avvia copertura di Robinhood con rating buy TD Cowen declassa Braze a hold dopo l’acquisizione da parte di CRM Rosenblatt avvia copertura su Robinhood con rating buy Rosenblatt avvia copertura su Robinhood con rating buy HUTCHMED chiude accordo di licenza da $110M con GSK per terapia oncologica RBC Capital taglia il rating di Mobileye per timori sul calcolo centralizzato
